Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Management and IR are outright lying now.

<< Previous

Bullboard Posts

Next >>

Post by Thejew on Jun 10, 2020 3:35pm

357 Views

Post# 31135160

Management and IR are outright lying now.

Well we now know management and IR totally lied about their options expiring, most were not, only a small percentage were. Now IR responded to me that "the offer of the bought deal was completely unsolicited and we had only a few hours to accept or decline, as is the nature of these offers." .......... So they really think we will believe they only had a few hours to approve or disapprove a $25M deal? IMO that is complete BS. And it was just a complete coincidence it was a week after they sold? HHHmmmmm K. I really thought this company was different and special for a penny stock, feeling pretty foolish right now.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for June 3, 2024